Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.54 |
| ▸ | HTR2B | P41595 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200574 | 0.88 | MEN1 (0.55) | HTR2CHTR2BMEN1KMT2AHTR2A | |
| SCHEMBL4023275 | 0.86 | MEN1 (0.57) | HTR2CHTR2BMEN1KMT2AHTR2A | |
| SCHEMBL3841383 | 0.84 | MAPK1 (0.60) | KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4267510 | 0.83 | MCHR1 (0.60) | KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4022252 | 0.83 | HTR2C (0.58) | HTR2CHTR2BHTR2A | |
| SCHEMBL4027655 | 0.82 | HTR2C (0.50) | HTR2CHTR2BKDM4EALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL5237943 | 0.81 | HTR2C (0.57) | HTR2CHTR2BHTR2A | |
| SCHEMBL5779141 | 0.81 | SIGMAR1 (0.63) | KDM4EALDH1A1KMT2A | |
| SCHEMBL4267324 | 0.81 | CYP2D6 (0.60) | HTR2CHTR2BKDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3859178 | 0.80 | SIGMAR1 (0.65) | KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | HTR2C 2/4885HTR2B 25/4885KDM4E 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.